Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

EPZ020411 (hydrochloride)

EPZ020411 hydrochloride is a selective inhibitor of PRMT6 with an IC50 of 10 nM, it has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 hydrochloride can be used for the research of cancer[1][2].

Product Specifications

CAS Number

2070015-25-5

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Histone Methyltransferase

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/EPZ020411-hydrochloride.html

Purity

98.15

Solubility

0.1 M HCl : 50 mg/mL (ultrasonic; warming; adjust pH to 2 with HCl; heat to 60°C) |DMSO : 50 mg/mL (ultrasonic) |H2O : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CNCCN(C)CC1=CNN=C1C2=CC=C(O[C@H]3C[C@H](OCCC4CCOCC4)C3)C=C2.Cl[H]

Molecular Formula

C25H39ClN4O3

Molecular Weight

479.06

Precautions

H302, H315, H319, H335

References & Citations

[1]Mitchell LH, et al. Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 ToolCompound. ACS Med Chem Lett. 2015 Apr 6;6 (6) :655-659.|[2]He Y, et al. Inhibition of Protein arginine methyltransferase 6 reduces reactive oxygen species production and attenuates aminoglycoside- and cisplatin-induced hair cell death. Theranostics. 2020 Jan 1;10 (1) :133-150.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, stored under nitrogen)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

PRMT1; PRMT6; PRMT8

Citation 01

J Immunother Cancer. 2025 Mar 13;13 (3) :e010639.|Acta Pharmacol Sin. 2022 Feb;43 (2) :457-469.|Bioorg Chem. 2024 May 10:148:107439.|Brain. 2024 Jul 5;147 (7) :2552-2565.|Cell Death Dis. 2023 Oct 9;14 (10) :655.|EMBO Rep. 2018 Dec;19 (12) :e46377.|Exp Cell Res. 2022 Nov 16;422 (1) :113413.|J Transl Med. 2024 Oct 10;22 (1) :922.|J Transl Med. 2025 Jan 16;23 (1) :74.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

MART-1 / Melan-A (M2-7C10), CF405S conjugate, 0.1mg/mL
BNC040009-100 1x 100 µL

MART-1 / Melan-A (M2-7C10), CF405S conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD45RO (190-2F2.5), CF405S conjugate, 0.1mg/mL
BNC041081-500 1x 500 µL

CD45RO (190-2F2.5), CF405S conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD95 (B-R18), CF405S conjugate, 0.1mg/mL
BNC040305-100 1x 100 µL

CD95 (B-R18), CF405S conjugate, 0.1mg/mL

Sign In for Pricing
View Details
Caldesmon, HMW (h-Caldesmon) (Smooth Muscle Marker) (rCALD1/820), CF740 conjugate, 0.1mg/mL
BNC741897-500 1x 500 µL

Caldesmon, HMW (h-Caldesmon) (Smooth Muscle Marker) (rCALD1/820), CF740 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
TCF4 (Transcription Factor 4) (TCF4/1705), CF488A conjugate, 0.1mg/mL
BNC881705-500 1x 500 µL

TCF4 (Transcription Factor 4) (TCF4/1705), CF488A conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD59 / Complement Regulatory Protein / Protectin (MACIF/2867R), CF488A conjugate, 0.1mg/mL
BNC882867-500 1x 500 µL

CD59 / Complement Regulatory Protein / Protectin (MACIF/2867R), CF488A conjugate, 0.1mg/mL

Sign In for Pricing
View Details